BioSig Technologies Appoints New Chief Medical Officer
Ticker: STEX · Form: 8-K · Filed: May 3, 2024 · CIK: 1530766
| Field | Detail |
|---|---|
| Company | Biosig Technologies, Inc. (STEX) |
| Form Type | 8-K |
| Filed Date | May 3, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, medical-device, clinical-strategy
TL;DR
BioSig snagged a new CMO, Dr. Amro Al-Ali, to push their EP system.
AI Summary
BioSig Technologies, Inc. announced on April 30, 2024, the appointment of Dr. Amro Al-Ali as Chief Medical Officer. Dr. Al-Ali, a practicing cardiologist, will lead the company's clinical strategy and research initiatives. This appointment is part of BioSig's ongoing efforts to advance its PURE EP™ System in the electrophysiology market.
Why It Matters
The appointment of a new Chief Medical Officer with clinical expertise is crucial for BioSig Technologies as it seeks to further develop and commercialize its PURE EP™ System, potentially impacting patient care and market adoption.
Risk Assessment
Risk Level: medium — The appointment of a key executive like a CMO can significantly influence a company's strategic direction and product development, carrying inherent risks related to execution and market reception.
Key Players & Entities
- BioSig Technologies, Inc. (company) — Registrant
- Dr. Amro Al-Ali (person) — Appointed Chief Medical Officer
- PURE EP™ System (product) — Company's electrophysiology system
- April 30, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of BioSig Technologies, Inc.?
Dr. Amro Al-Ali has been appointed as the new Chief Medical Officer of BioSig Technologies, Inc.
What is the effective date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing is dated April 30, 2024.
What is the primary focus of Dr. Amro Al-Ali's role as Chief Medical Officer?
Dr. Al-Ali will lead the company's clinical strategy and research initiatives, focusing on the PURE EP™ System.
What industry does BioSig Technologies, Inc. operate in?
BioSig Technologies, Inc. operates in the electromedical and electrotherapeutic apparatus industry, specifically with its PURE EP™ System for electrophysiology.
What is the state of incorporation for BioSig Technologies, Inc.?
BioSig Technologies, Inc. is incorporated in Delaware.
Filing Stats: 735 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2024-05-03 08:30:11
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BSGM The NASDAQ Capital M
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex99-1.htm (EX-99.1) — 17KB
- 0001493152-24-017634.txt ( ) — 234KB
- bsgm-20240430.xsd (EX-101.SCH) — 3KB
- bsgm-20240430_lab.xml (EX-101.LAB) — 33KB
- bsgm-20240430_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOSIG TECHNOLOGIES, INC. Date: May 3, 2024 By: /s/ Anthony Amato Name: Anthony Amato Title: Chief Executive Officer